Medicine:IVX-411
From HandWiki
Short description: COVID-19 nanoparticle vaccine candidate
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | vlp |
| Clinical data | |
| Routes of administration | Intramuscular |
IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia.[1] It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.[2][3][4]
References
- ↑ "ANZCTR - Registration". https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000738820.
- ↑ "Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc." (in en). https://investors.icosavax.com/news-releases/news-release-details/icosavax-initiates-phase-12-trial-covid-19-vlp-vaccine-candidate/.
- ↑ "Two nanoparticle vaccines enter clinical trials" (in en-US). Institute for Protein Design. https://www.ipd.uw.edu/2021/06/two-nanoparticle-vaccines-enter-clinical-trials/.
- ↑ "Adjuvanting a subunit COVID-19 vaccine to induce protective immunity". Nature 594 (7862): 253–258. June 2021. doi:10.1038/s41586-021-03530-2. PMID 33873199. Bibcode: 2021Natur.594..253A.
 |
